Navigation Links
BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference

SAN DIEGO--(BUSINESS WIRE)--May 22, 2007 - BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today data from its Phase I trial of BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. The trial demonstrated that the compound was well tolerated and demonstrated biochemical evidence of dopamine blockade which is indicative of efficacy. BioLineRx presented the data in a poster (Abstract 235 XX) at the 2007 American Psychiatric Association (APA) Annual Meeting, which is being held May 19-24 in San-Diego, CA. A Phase II clinical trial for BL-1020 to determine the maximum tolerated dose in schizophrenic patients is expected to begin in the end of June, 2007.

"We are pleased to be presenting these promising results for BL-1020 at the APA Annual Meeting and look forward to the imminent initiation of the Phase II trial for this compound," commented Morris C. Laster, M.D., chief executive officer of BioLineRx.

The results of this trial were as follows:

1. BL-1020 demonstrated dopamine blockade by dose dependant elevation in serum prolactin levels which serves as a surrogate marker for dopamine antagonism. Dopamine hyperactivity is implicated in schizophrenia, and is the mechanism of action for various antipsychotic drugs.

2. In this trial BL-1020 appeared to be protective against extrapyramidal symptoms, a severe side effect of many antipsychotic medications. BL-1020 was extremely well tolerated in that no ECG psychiatric or neurological abnormalities were seen at any of the doses tested.

About the BL-1020 Phase I Clinical Trial

The Phase 1 trial of BL-1020 was a randomized, double blind, placebo-controlled, dose-escalation, single center study in healthy adult males (ages 21-45). The primary objective was to evaluate the safety and tolerability of escalating doses of BL-1020. The secondary objectives were to
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic cancers and women,s health, has appointed Holly ... Managed Markets. Ms. Bauzon has a proven ... payer coverage for laboratory services companies. She has more ... PerkinElmer, Inc., where she held the position of Director, ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ... company, announced today that it has completed integration ... solution for Plastic Surgery and Dermatology practices. ... more value to healthcare practices using Nextech," stated ... eRelevance Corporation. "Using information from the EMR we ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... A new study finds a wide range of ... related to key environmental exposuresin children with Crohn,s disease (CD), ... of the Crohn,s & Colitis Foundation of America ... & Wilkins , a part of Wolters Kluwer Health ... alterations of DNA in several regions of the genome in ...
(Date:8/22/2014)... images of nurses at New York University,s Langone Medical ... many including the youngest and most vulnerable down flights ... storm surge generated by Hurricane Sandy. , Now, ... University Colleges of Nursing (NYUCN) and of Dentistry (NYUCD), ... examines the impact on NYULMC nurses, post-Sandy deployment to ...
(Date:8/22/2014)... Oldsmar, FL (PRWEB) August 22, 2014 ... Cryo-Cell’s cell therapy research affiliate, Saneron CCEL Therapeutics, Inc. ... agreement. , “Cryo-Cell is extremely pleased to collaborate with ... an IND, which we hope will lead to regenerative ... neurodegenerative diseases such as ALS,” David Portnoy, Chairman and ...
(Date:8/22/2014)... News) -- The U.S. Drug Enforcement Administration (DEA) is ... hydrocodone, which has been tied to a surge in ... restrictions would cover prescription narcotic drugs such as Vicodin, ... same regulatory class as painkillers such as Oxycontin, Percocet ... a three-month supply of the drug and will have ...
Breaking Medicine News(10 mins):Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 2Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 3
... - New Hayfever Relief Product Based on Acupressure ... , - With Photo , ... it,s believed that,it now affects as many as 1 in 4 ... either complete misery with symptoms such as reduced,concentration, runny nose and ...
... Improvement Firm Recognizes Efforts in Patient SatisfactionSOUTH BEND, Ind., ... Press Ganey Associates, Inc., is proud to recognize all ... improving the quality of care they provide."The doctors, nurses, ... to improve quality, and they deserve to be commended," ...
... urged to prevent head, neck injuries , , SUNDAY, May ... help prevent head and neck injuries related to recreational ... year in the United States, about 1.5 million people ... and nearly 12,000 are treated for neck fractures, according ...
... Support the Nancy Davis Foundation for Multiple Sclerosis LOS ... the world,s most exclusive super sport cars, donated the ... to support the Nancy Davis Foundation for Multiple Sclerosis ... charity event at the Hyatt Regency Century Plaza in ...
... thwart hospital ,superbugs, viruses and mold, scientists say ... paint kills disease-causing bacteria, mold, fungi and viruses, said ... claim their paint, which can be used in homes, ... so-called "superbugs," antibiotic-resistant microbes that are found in hospitals ...
... free workshops with an emphasis on smoking cessation to raise public ... in order to improve their quality of life. , ... ... consecutive year, May 2009 has been designated Stroke Awareness Month. During ...
Cached Medicine News:Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 2Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 3Health News:Press Ganey Supports National Hospital Week 2Health News:Press Ganey Supports National Hospital Week 3Health News:Ladders, Swings and More Can Cause Peril 2Health News:First U.S. Lamborghini Gallardo LP 560-4 Spyder Auctioned at Race to Erase MS Charity Event 2Health News:Health Care Professionals Offer Free Consultations for National Stroke Awareness Month 2
... Medical is the world leader in ... used worldwide for permanent pacemaker and ... and port implantation, and for temporary ... St. Jude Medical Peel-Away introducers includes ...
... Self-Expanding Stent System combines low-profile, high radial force, ... guide wire compatible stent system provides 6F sheath ... (5.0 - 10.0 mm). Now, with longer stents ... five stent lengths (28, 38, 56, 80 and ...
... A particular challenge in transseptal left heart ... must be exchanged for a sheath with ... wall position. Traditionally, such an exchange has ... heparinized patient. Biosense Webster has overcome this ...
Coaxial Multicolor LIO Worlds first coaxial multicolor LIO provides precise laser delivery with repeatable outcomes, as well as maximum treatment options and physician safety....
Medicine Products: